openPR Logo
Press release

direct/ Stem Cell Innovations, Inc. (UK) - STEM CELL INNOVATIONS MAKES THEIR HUMAN EMBRYONIC GERM CELL PLATFORM COMMERCIALLY AVAILABLE IN EUROPE

At Bio2006 Stem Cell Innovations, Inc. (SCLL.OB) announced today that the Company will commercialize their proprietary platform of human pluripotent stem cells in Europe through their newly established European R & D facility in Leiden, the Netherlands.

CEO Dr. James Kelly recently disclosed that SCI has produced multiple lines of human pluripotent stem cells. These cell lines are able to maintain their undifferentiated state and normal chromosome complement. The cells are produced without feeder layers (xenofree). The company is able to efficiently develop multiple lines, the first step in creating banks of cells that can be matched to patients in cell therapies.

To be able to serve the European market and to make the cells available to both scientists in Academia and the European Pharma and Biotech industry, SCI will produce stem cell lines in Leiden as well as in Houston, Texas.

Contact USA:
Dr. James H. Kelly, Chief Executive Officer
T +1 281 679 7900


Contact Europe:
Emmie van Halder, Business Development
M +31 6 53 202 105, T +31 70 322 8050

Ellen de Waal, PR & Corporate Communications
M +31 6 54 711 703, T +31 70 356 1534

About Stem Cell Innovations, Inc.
Stem Cell Innovations, through its wholly owned subsidiary, Amphioxus Cell Technologies, which is based in Houston, Texas, is a cell biology company. It utilizes its proprietary C3A human liver cell line in the field of drug discovery and toxicology testing and is also engaged in the development and production of its proprietary PC(TM) pluripotent stem cells. These human cell-based disease models create a platform for the discovery, testing and development of all therapeutic modalities including small molecules, cell-based therapeutics, small interfering RNAs and antibodies.

www.stemcellinnovations.com

pdf-version press release

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company´s periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the differences could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.






The announcement distributed by directnews.
The issuer is solely responsible for the content of this announcement.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release direct/ Stem Cell Innovations, Inc. (UK) - STEM CELL INNOVATIONS MAKES THEIR HUMAN EMBRYONIC GERM CELL PLATFORM COMMERCIALLY AVAILABLE IN EUROPE here

News-ID: 7728 • Views:

More Releases from Stem Cell Innovations, Inc. (UK)

direct/ Stem Cell Innovations, Inc. (UK) - Stem Cell Innovations officially open …
Leiden, The Netherlands - June 1, 2006 - Stem Cell Innovations, Inc. (SCLL.OB) announced yesterday that the Company has opened a new R&D facility to commercialise their proprietary platform of human pluripotent stem cells (PCs(TM)) in Europe. The facility is based in Leiden, the Netherlands and encompasses 1,000 m2 of state-of-the-art research laboratories. "Establishing a site in Europe is part of SCI´s strategy to become a global leading player in
direct/ Stem Cell Innovations, Inc. (UK) - Stem Cell Innovations, Inc. files pat …
CELLS MAY BE USEFUL IN THERAPIES FOR ALS, PARKINSON´S, MULTIPLE SCLEROSIS AND OTHER NEURODEGENERATIVE DISEASES. SCOTCH PLAINS, NJ - April 27, 2006 - Stem Cell Innovations, Inc. (OTCBB: SCLL) has filed a patent application protecting the differentiation of its proprietary human pluripotent stem cells (PCs) into neural progenitor cells and purified populations of motor neurons. These cells will initially be used in the Company´s core drug discovery and toxicology platform.

More Releases for Europe

2019 Strategy Consulting Market Analysis | McKinsey, The Boston Consulting Group …
Strategy Consulting Market reports also offer important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends Need for strategic planning in highly competitive environment and to develop business capabilities to meet & exceed the emerging requirements are the major drivers which help in surging
Strategy Consulting Market 2025 | Analysis By Top Key Players: Booz & Co. , Rola …
Global Strategy Consulting Market 2019-2025, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. The key players covered in this study McKinsey , The Boston Consulting Group , Bain & Company , Booz & Co. , Roland Berger Europe
Digital Strategy Consulting Market is Thriving Worldwide with Deloitte, McKinsey …
A Digital Strategy is a form of strategic management and a business answer or response to a digital question, often best addressed as part of an overall business strategy. A digital strategy is often characterized by the application of new technologies to existing business activity and focus on the enablement of new digital capabilities to their business. A new report as a Digital Strategy Consulting market that includes a comprehensive analysis
Strategy Consulting Market 2019: By McKinsey, The Boston Consulting Group, Bain …
This report studies the global Strategy Consulting market, analyzes and researches the Strategy Consulting development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like • McKinsey • The Boston Consulting Group • Bain & Company • Booz & Co. • Roland Berger Europe • Oliver Wyman Europe • A.T. Kearney Europe • Deloitte • Accenture Europe Get Sample Report@ https://www.reporthive.com/enquiry.php?id=1247388&req_type=smpl&utm_source=AB Market segment by Type, the product can be split into • Operations Consultants • Business Strategy Consultants • Investment Consultants • Sales and
Strategy Consulting Market Analysis 2018: McKinsey, The Boston Consulting Group, …
Orbis Research Present’s “Global Strategy Consulting Market” magnify the decision making potentiality and helps to create an effective counter strategies to gain competitive advantage. The global Strategy Consulting status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Strategy Consulting development in United States, Europe and China. In 2017, the global Strategy Consulting market size was million US$ and it is expected to reach million
Influenza Vaccination Market Global Forecast 2018-25 Estimated with Top Key Play …
UpMarketResearch published an exclusive report on “Influenza Vaccination market” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 115 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. This report focuses on the Influenza Vaccination market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This